Researchers develop light-activated Parkinson’s drug

News

Author: Simge Eva DoganPublished: 18 July 2018

Prep: Cook: Serves:

A new light-activated drug for treating Parkinson’s has been developed by a research team led by the University of Barcelona, Spain.

The drug – named MRS7145 – is placed within a brain implant and then activated by shining a light on it.

The effect of the newly developed drug was tested on live mice to see if it could improve their motor function. The results – published in ‘Journal of Controlled Release’ – showed that MRS7145 reduced tremors and seizures and improved the mice’s ability to walk.

Professor Francisco Ciruela, researcher at the Faculty of Medicine and Health Sciences of the University of Barcelona, Spain, said he envisaged the drug being administered by smart phones, with “the doctor (controlling) in a precise manner the release of the most efficient dose of the active drug in the place of action”.

For more information on Parkinson’s research please visit the EPDA website.

Last Month

Next Month

Go Back

Share this story

Comments

Europe

“The beginning of a wonderful collaboration between countries, organisations and people”

The EPDA hosted a two-day event last week

Parkinson’s in the news: June

A roundup of Parkinson’s news stories in June

6 works of art shedding light on Parkinson’s

How are artists around the world portraying Parkinson’s?

Is sleepwalking linked to risk of Parkinson’s disease in men?

Men who sleepwalk may be at a greater risk of developing Parkinson’s disease, according to a new study from researchers in the US. The team assessed Mayo Clinic sleep questionnaire survey answers from 25,694 men, 1% of whom had been diagnosed with Parkinson’s disease. They found that men who experienced sleepwalking were four times more likely to have Parkinson’s, and those with probable REM sleep behaviour disorder – a condition where sleepers experience sudden body movements while dreaming – were six times more likely. For those who experienced both sleepwalking and REM sleep behaviour disorder, the risk increased to eight times more likely. “We need further studies to understand this,” said senior author, Dr Xiang Gao. “Particularly to see whether sleepwalking occurs before Parkinson’s onset, and the number of individuals with sleepwalking who eventually develop Parkinson’s and other neurodegenerative diseases.”

Stay tuned for series two of the Parkinson’s Life podcast

The award-winning Parkinson’s Life podcast is back this month. Helping to amplify the voices of the international Parkinson’s community, the podcast has so far reached more than 12,000 people around the world. Thanks to the support of pharmaceutical companies, and the backing of a grant from the Boston Scientific Foundation Europe, the second series will bring together people with Parkinson’s disease and experts in their field to explore topics such as sleep hygiene, exercise and mental health, and to offer advice to listeners. Sandrine Bazile, president of the Boston Scientific Foundation Europe, says: “We fully support this project because it mirrors perfectly our mission to improve patient wellbeing using innovative solutions. We believe in the importance of the [Parkinson’s Life] podcast series, with its aim to improve the information and education available to people with Parkinson’s and their families – to help them live life to the full.”

How Parkinson’s disease could impact the way you see art

A new study from a team at the University of Pennsylvania’s Perelman School of Medicine, US, has indicated that Parkinson’s disease could affect the way people experience art. The researchers asked 43 people with the condition and 40 controls to make judgements about 10 paintings by American artist Jackson Pollock and 10 by Dutch painter Piet Mondrian, rating them according to factors including liking, beauty, motion, complexity and colour-saturation. The participants with Parkinson’s showed more of a preference for ‘high-motion’ art. They also showed a lower recognition of movement compared to controls, suggesting that the brain’s motor system may help interpret movement from static visual cues. However, the research team noted that many of the participants were on their usual medication, and that the impact of dopamine agonists on the experience of art would also need to be considered.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

Researchers develop light-activated Parkinson’s drug

News

Author: Simge Eva DoganPublished: 18 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Europe

“The beginning of a wonderful collaboration between countries, organisations and people”

Global update

Parkinson’s in the news: June

Global update

6 works of art shedding light on Parkinson’s

Is sleepwalking linked to risk of Parkinson’s disease in men?

Stay tuned for series two of the Parkinson’s Life podcast

How Parkinson’s disease could impact the way you see art

{title}

Subscribe

Researchers develop light-activated Parkinson’s drug

News

Author: Simge Eva DoganPublished: 18 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Europe

“The beginning of a wonderful collaboration between countries, organisations and people”

Global update

Parkinson’s in the news: June

Global update

6 works of art shedding light on Parkinson’s

Is sleepwalking linked to risk of Parkinson’s disease in men?

Stay tuned for series two of the Parkinson’s Life podcast

How Parkinson’s disease could impact the way you see art

{title}

Subscribe

Sign in